Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09NVU
|
|||
| Former ID |
DIB010959
|
|||
| Drug Name |
ZP-1848
|
|||
| Synonyms |
Glucagon-like peptide-2 analog (inflammatory bowel disease/ Crohn's disease), Zealand
Click to Show/Hide
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 1 | [1] | |
| Company |
Zealand Pharma A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 2 receptor (GLP2R) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (s) signalling events | |||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00868660) Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose. | |||
| REF 2 | US patent application no. 8,580,918, Peptidic glp-2 agonists. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.